Compare First Citizens BancShares Inc (FCNCA) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Citizens BancShares Inc vs Novo Nordisk A/S — how do they compare? First Citizens BancShares Inc trades at $2,249.28 (market cap $25.04B), while Novo Nordisk A/S trades at $45.76 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 8.3× First Citizens BancShares Inc's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| FCNCA | NVO | |
|---|---|---|
Market Cap | $25.04B | $207.85B |
Sector | Sector/Thematic | Health |
52-Week High | $2.25K | $63.98 |
52-Week Low | $1.64K | $35.29 |
Dividend Yield | 0.37% | 3.81% |
Enterprise Value | — | $222.55B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Citizens BancShares (FCNCA) trades at $2,218.49, down 0.85% on the day, with strong technical indicators showing a bullish trend. The company demonstrates solid fundamentals with a P/E of 11.98, net income margin of 25.23%, and consistent earnings beats in recent quarters. Recent business developments include expansion of working capital finance services and strategic leadership appointments to drive growth across central U.S. markets.
FCNCA presents a mixed outlook with strong profitability metrics and positive earnings momentum offset by cautious analyst sentiment (81.82% hold rating). The stock trades below consensus price target of $2,310, offering potential upside, though risks include contracting net interest margins and elevated uninsured deposits at 38.3% of total deposits.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Citizens BancShares Inc
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
